Skip to main content
TCNNF
OTC Life Sciences

Trulieve Cannabis Returns to Profitability in Q1 2026, Reports Strong Cash Flow and Positive Regulatory Outlook

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
8
Price
$9.79
Mkt Cap
$1.883B
52W Low
$3.25
52W High
$11.83
Market data snapshot near publication time

summarizeSummary

Trulieve Cannabis Corp. announced a return to GAAP net profitability in Q1 2026, reporting $2 million in net income and strong cash flow, alongside positive regulatory developments for the cannabis industry.


check_boxKey Events

  • Return to GAAP Net Profitability

    The company reported a net income attributable to common shareholders of $2 million for Q1 2026, a significant improvement from net losses of $42.9 million in Q4 2025 and $32.9 million in Q1 2025.

  • Strong Cash Flow Generation

    Trulieve generated $56 million in cash flow from operations and $42 million in free cash flow during the quarter, ending with a cash balance of $353 million.

  • Positive Regulatory Developments

    Management highlighted the reclassification of medical marijuana to Schedule III, noting the company's strong positioning with 206 medical dispensaries to capitalize on new opportunities.

  • Solid Financial Outlook

    The company anticipates low single-digit revenue growth for Q2 2026 and expects at least $250 million in cash flow from operations for the full year 2026.


auto_awesomeAnalysis

Trulieve Cannabis Corp. reported a significant turnaround in its first quarter 2026 financial results, achieving GAAP net income of $2 million compared to substantial losses in prior periods. This return to profitability, coupled with robust cash flow from operations of $56 million and a healthy cash balance of $353 million, signals improved financial health and operational efficiency. The company also highlighted the positive impact of the Trump Administration's reclassification of medical marijuana to Schedule III, a development that could open new opportunities for Trulieve, which operates 206 medical dispensaries. The outlook for Q2 revenue growth and strong full-year cash flow further reinforces a positive trajectory for the company.

At the time of this filing, TCNNF was trading at $9.79 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $3.25 to $11.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed TCNNF - Latest Insights

TCNNF
May 07, 2026, 6:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
TCNNF
May 07, 2026, 6:19 AM EDT
Filing Type: 8-K
Importance Score:
8
TCNNF
May 07, 2026, 6:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
TCNNF
Mar 05, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
7
TCNNF
Feb 26, 2026, 6:25 AM EST
Filing Type: 10-K
Importance Score:
8
TCNNF
Feb 26, 2026, 6:18 AM EST
Filing Type: 8-K
Importance Score:
8
TCNNF
Jan 29, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7